Reimbursement news and insurance coverage updates.
CareDx Stock Rises Following American Society of Transplant Surgeons' Position Statement on Test Use
ASTS supports the use of dd-cfDNA as a biomarker of kidney transplant rejection, as well as peripheral blood gene expression profiling to help rule out heart transplant rejection.
MolDx Reimbursement Decision Likely to Have Negative Impact on CareDx, Natera Transplant Businesses
MolDx updated its guidance for rejection risk molecular testing with more restrictive language, potentially ending multimodal test coverage.
Natera's Signatera Gains First Commercial Payor Coverage in California, Louisiana
Blue Shield of California and Blue Cross and Blue Shield of Louisiana are each covering Signatera for multiple cancer indications.
National Government Services Expands Coverage for Bio-Techne's ExoDx Prostate Cancer Test
The assay will now be covered for patients with at least one prior negative biopsy who are considering a repeat biopsy and are thought to be at higher risk.
Medicare to Cover Natera's Signatera MRD Test in Breast Cancer
The payor will reimburse serial monitoring in all subtypes, including HER2-positive and triple-negative breast cancers, in patients with stage IIb or higher tumors.